97 -10 (84) 2025 - R.Z. Mirzayev, E.N.Tashkenbayeva - ANALYSIS AND MODIFICATION OF METABOLIC AND HEMODYNAMIC RISK FACTORS FOR THE PROGRESSION OF CKD IN PATIENTS WITH TYPE 2 DM

ANALYSIS AND MODIFICATION OF METABOLIC AND HEMODYNAMIC RISK FACTORS FOR THE PROGRESSION OF CKD IN PATIENTS WITH TYPE 2 DM

R.Z. Mirzayev - Samarkand State Medical University

E.N.Tashkenbayeva - Samarkand State Medical University

Resume

Type 2 diabetes mellitus (T2DM) remains the leading cause of chronic kidney disease (CKD) worldwide and one of the main determinants of cardiovascular mortality. Up to one-third of patients with type 2 diabetes develop diabetic kidney disease throughout their life, and the combination of decreased glomerular filtration rate (GFR) and albuminuria significantly increases the risk of terminal renal failure, cardiovascular events, and premature death. A particular problem is the "silent" nature of the early stages of CKD and the high proportion of patients with residual risk of progression even against the background of standard therapy.

Keywords: type 2 diabetes mellitus, diabetic nephropathy, chronic kidney disease, metabolic factors, hemodynamic disorders, albuminuria, glomerular filtration rate, renin-angiotensin system

First page

554

Last page

558

For citation:R.Z. Mirzayev, E.N.Tashkenbayeva - ANALYSIS AND MODIFICATION OF METABOLIC AND HEMODYNAMIC RISK FACTORS FOR THE PROGRESSION OF CKD IN PATIENTS WITH TYPE 2 DM //New Day in Medicine 10(84)2025 554-558 https://newdayworldmedicine.com/en/new_day_medicine/10-84-2025

List of References

1. Shestakova M.V., Shamkhalova M.Sh., Yarek-Martynova I.R. et al. Algorithms of Specialized Medical Care for Patients with Diabetes Mellitus / Edited by I.I. Dedov, M.V. Shestakova, A.Yu. Mayorov. - 10th issue // Diabetes Mellitus. 2021;24(1S):1-144.
2. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease // Kidney Int. – 2022;102(5S):1-127.
3. Tuttle K.R., Brosius F.C., Adler S.G. et al. JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results of a Phase 2 randomized controlled clinical trial // Nephrol. Dial. Transplant. 2023;38(12):2743-2752.
4. Rossing P., Caramori M.L., Chan J.C. et al. Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence // Kidney Int. 2022;102(5):990-999.
5. Mukhin N.A., Moiseev V.S., Kobalava Zh.D. et al. Cardiorenal relationships: clinical significance and role in the pathogenesis of cardiovascular system and kidney diseases // Clinical Nephrology. – 2021;2:5-29.
6. Heerspink H.J.L., Stefánsson B.V., Correa-Rotter R. et al. Dapagliflozin in patients with chronic kidney disease // N. Engl. J. Med. 2020;383(15):1436-1446.
7. Perkovic V., Jardine M.J., Neal B. et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy // N. Engl. J. Med. 2019;380(24):2295-2306.
8. Bikbov B.T., Tomilina N.A. The State of Replacement Therapy in Patients with Chronic Kidney Failure in the Russian Federation in 2018-2020 (Report on the Data of the All-Russian Register of Replacement Kidney Therapy of the Russian Dialysis Society, part one) // Nephrology and Dialysis. - 2022. - Vol. 24, No3. - P. 268-333.
9. Zinman B., Wanner C., Lachin J.M. et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes // N. Engl. J. Med. 2015;373(22):2117-2128.
10. Smirnov A.V., Dobronravov V.A., Rumyantsev A.Sh. et al. National recommendations. Chronic kidney disease: main principles of screening, diagnosis, prevention and treatment approaches // Clinical Nephrology. 2021;1:4-50.

    file

    download